… In summary, sulbactam-durlobactam demonstrated potent antibacterial activity against a …
clinical isolates of ABC isolates, including carbapenem-non-susceptible and MDR isolates. …

… Sulbactam/durlobactam has demonstrated favourable safety, … the activity of the
sulbactam/durlobactam combination in … , non-duplicate, global isolates of carbapenem-resistant A. …

… isolates, the addition of durlobactam to sulbactam lowered the MIC 90 compared to that of
sulbactam … Over half of these isolates were nonsusceptible to carbapenems, with only 47.4% …

… Amongst the 25 resistant isolates, we identified a number of mechanisms which may be
contributing factors, in particular PBP substitutions and the production of specific beta-…

… sulbactam. To date, susceptibility data for sulbactam/durlobactam have been limited to isolates
… Although a global problem, infections caused by carbapenem-resistant A. baumannii are …

… global surveillance study of 5,032 ABC clinical isolates … Molecular characterization of these
isolates confirmed the primary … confer sulbactam resistance and that the efflux of durlobactam …

… sulbactam-durlobactam (SD) combination has recently completed Phase 3 testing in the global
… Results: Durlobactam restored sulbactam activity against the majority of the strains tested…

… A recent analysis of 84 non-clonal, globally diverse clinical isolates from 2006 to 2014 …
The rare isolates with elevated sulbactam-durlobactam MICs were found to encode either …

… against ABC isolates and sulbactam/durlobactam is not active against ABC isolates that …
, aztreonam, ceftazidime and sulbactam in a global random selection of clinical isolates of A. …

… a global threat to human health. CRAb is emerging worldwide, and the majority of these
isolates show … However, colistin-resistant isolates are emerging worldwide [19]. The intravenous …